Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
D. Bagnasco (Genoa, Italy), F. Menzella (Reggio Emilia, Italy), M. Caminati (Verona, Italy), M. Bonavia (Arenzano, Italy), G. Guida (Turin, Italy), C. Caruso (Rome, Italy), G. Passalacqua (Genoa, Italy). Switch Omalizumab – Mepolizumab: real life experience. 1656

Member's Comments

No comment yet.

Related content which might interest you: Omalizumab in severe asthma: real life study Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Omalizumab in practice: learning from experience Source: Annual Congress 2007 - Changing practice with anti-IgE: patient, physician and payor perspectives Year: 2007 Real life experience with omalizumab and mepolizumab in severe asthma : do patient baseline features preclude effectiveness comparison ? Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 When omalizumab is effective, should treatment be for life? Source: International Congress 2018 – Asthma management Year: 2018 Late Breaking Abstract - Patients with severe eosinophilic asthma benefit from the treatment with Anti-IL-5 Reslizumab – a real life study from Austria Source: International Congress 2018 – Notable Studies in Asthma Year: 2018 Effectiveness evaluation of anti-IgE treatment at 3rd year: Real life Turkey data Source: International Congress 2016 – Asthma points to ponder Year: 2016 Long Term Sirolimus therapy for LAM: a real life experience Source: International Congress 2017 – Rare diseases Year: 2017 Real-world outcomes in patients receiving omalizumab for allergic asthma in India: Analysis by baseline IgE level Source: Annual Congress 2013 –Treatment of asthma Year: 2013 Asthma treatment in real life Source: International Congress 2018 – Primary care management of asthma Year: 2018 Tiotropium + olodaterol fixed-dose combination shows clinically meaningful improvements in quality of life versus placebo Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015 Late Breaking Abstract - Extrafine single inhaler triple therapy improves quality of life in COPD. Analysis of SGRQ subdomains of the TRIBUTE Study Source: International Congress 2018 – COPD: from LABA/ICS to LABA/LAMA/ICS Year: 2018 Fluticasone propionate/formoterol therapy for asthmatic patients: Results of a non-interventional study Source: International Congress 2016 – Asthma management Year: 2016 Late Breaking Abstract - Durable clinical benefit of benralizumab following oral corticosteroid reduction: The PONENTE study Source: Virtual Congress 2021 – Severe asthma: evaluation using patient-reported outcome measures (PROMs) and biomarkers, comorbidities and treatments Year: 2021 The real world effectiveness and effect on adherence with inhaled asthma therapy of 1 year of Severe Asthma Monoclonal Antibody Treatment Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020 Single inhaler triple therapy in patients with COPD: response rates in health-related quality of life in the IMPACT Trial Source: International Congress 2018 – Clinical trials in COPD: new results Year: 2018 Valuing the real world benefits of omalizumab Source: Annual Congress 2007 - Changing practice with anti-IgE: patient, physician and payor perspectives Year: 2007 Omalizumab improves asthma-specific quality of life in patients with severe allergic asthma Source: Eur Respir J 2001; 18: Suppl. 33, 37s Year: 2001 Adherence to COPD controller therapy: real life setting Source: International Congress 2019 – Inhalers: adherence and preference Year: 2019 Use of Omalizumab in children in real clinical practice. Source: Virtual Congress 2021 – Paediatric allergic asthma: novel therapeutics and monitoring approaches Year: 2021 Uncovering the reality of life with severe asthma Source: International Congress 2016 – Exploring mechanisms in health and disease Year: 2016